Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • Drug which prevents...

    Drug which prevents muscle scarring is a new hope for Heart failure

    Written by Anjali Nimesh Nimesh Published On 2017-10-31T19:05:07+05:30  |  Updated On 31 Oct 2017 7:05 PM IST
    Drug which prevents muscle scarring is a new hope for Heart failure

    A potential treatment to prevent deadly muscle scarring that contributes to chronic heart failure has been uncovered by scientists.The therapy could also prevent scarring of the skeletal muscles we use to move our arms and legs, a cause of long-term disabilities.




    The treatment works by targeting molecules on the surface of scar-forming cells, called alpha V integrins. A research team, led by the University of Edinburgh, found that blocking these molecules with a new experimental drug helped to reduce scarring following heart or skeletal muscle injury.


    The treatment works even when the muscle scarring process has already started, the research with mice found.The next step will be to test the drug in clinical trials with people to check whether it can help to reduce scarring in patients with chronic heart failure, and also patients with skeletal muscle scarring.


    Scarring is a natural response to tissue injury, but in excess it can stop muscles from working effectively.


    In many people excessive scarring -- known as fibrosis -- is permanent, and causes muscles to become stiff and less compliant.


    When fibrosis occurs in cardiac muscle during chronic heart failure, the heart muscle is less able to contract properly and pump blood around the body.


    The team found that scarring is initiated by cells around the lining of blood vessels, which have alpha V integrins on their surface.


    Lab tests on human cells of this type -- called mesenchymal cells -- found that blocking alpha V integrins stops them from becoming activated and blocks the scarring process.


    The study, published in Nature Communications, was supported by the Wellcome Trust and the British Heart Foundation. Funding was also received from the Royal College of Surgeons of Edinburgh.


    Professor Neil Henderson, of the Medical Research Council Centre for Inflammation Research at the University of Edinburgh, said: "Cardiac fibrosis is a major contributor to chronic heart failure, which is a major cause of death worldwide. Our research has identified a promising therapeutic target in the development of new treatments for patients with chronic heart failure."


    Professor Jeremy Pearson, Associate Medical Director at the British Heart Foundation said: "Scarring of the heart muscle has a major impact on the heart's ability to pump effectively. This can lead to heart failure and there is no effective treatment at the moment. By finding a new way to limit scarring in the hearts of mice, this research has unlocked the route to a potential treatment for this life-threatening problem."


    For more details click on the link : I. R. Murray, Z. N. Gonzalez, J. Baily, R. Dobie, R. J. Wallace, A. C. Mackinnon, J. R. Smith, S. N. Greenhalgh, A. I. Thompson, K. P. Conroy, D. W. Griggs, P. G. Ruminski, G. A. Gray, M. Singh, M. A. Campbell, T. J. Kendall, J. Dai, Y. Li, J. P. Iredale, H. Simpson, J. Huard, B. Péault, N. C. Henderson. αv integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis. Nature Communications, 2017; 8 (1) DOI: 10.1038/s41467-017-01097-z



    Cardiac fibrosischronic heart failurefibrosisHeart failure therapyjournal Nature CommunicationsMedical Research Council CentreNature CommunicationsRoyal College of SurgeonsUniversity of Edinburgh

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Anjali Nimesh Nimesh
    Anjali Nimesh Nimesh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok